These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38102675)

  • 1. Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab.
    Gentile I; Foggia M; Silvitelli M; Sardanelli A; Cattaneo L; Viceconte G
    Virol J; 2023 Dec; 20(1):301. PubMed ID: 38102675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.
    Mikulska M; Sepulcri C; Dentone C; Magne F; Balletto E; Baldi F; Labate L; Russo C; Mirabella M; Magnasco L; Di Grazia C; Ghiggi C; Raiola AM; Giacobbe DR; Vena A; Beltramini S; Bruzzone B; Lemoli RM; Angelucci E; Bassetti M
    Clin Infect Dis; 2023 Jul; 77(2):280-286. PubMed ID: 36976301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients.
    Lanzafame M; Gottardi M; Guella L; Collini L; Costa G; Guella A; Vento S
    J Chemother; 2023 Nov; 35(7):623-626. PubMed ID: 37102326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies.
    Aiello TF; Peyrony O; Chumbita M; Monzó P; Lopera C; Puerta-Alcalde P; Magnano L; Fernández-Avilés F; Cuesta G; Tuset M; Mensa J; Esteve J; Marcos MA; Soriano A; Garcia-Vidal C
    Influenza Other Respir Viruses; 2024; 18(3):e13264. PubMed ID: 38468434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients.
    Piñana JL; Heras I; Aiello TF; García-Cadenas I; Vazquez L; Lopez-Jimenez J; Chorão P; Aroca C; García-Vidal C; Arroyo I; Soler-Espejo E; López-Corral L; Avendaño-Pita A; Arrufat A; Garcia-Gutierrez V; Arellano E; Hernández-Medina L; González-Santillana C; Morell J; Hernández-Rivas JÁ; Rodriguez-Galvez P; Mico-Cerdá M; Guerreiro M; Campos D; Navarro D; Cedillo Á; Martino R; Solano C;
    Viruses; 2023 Oct; 15(10):. PubMed ID: 37896843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study.
    Drysdale M; Tibble H; Patel V; Gibbons DC; Lloyd EJ; Kerr W; Macdonald C; Birch HJ; Sheikh A
    BMC Infect Dis; 2024 Jul; 24(1):670. PubMed ID: 38965495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does early combination vs. Monotherapy improve clinical outcomes of clinically extremely vulnerable patients with COVID-19? Results from a retrospective propensity-weighted analysis.
    Maria M; Maraolo AE; Cozzolino C; Sasset L; Ferrari A; Basso M; Vania E; Bonadiman N; Scaglione V; Cattelan AM
    Eur J Med Res; 2024 Oct; 29(1):484. PubMed ID: 39367485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients.
    Huygens S; Gharbharan A; Serroukh Y; Snoek B; Franken B; Oude Munnink BB; Van Hagen PM; Bogers S; Geurtsvankessel CH; Rijnders BJA
    J Antimicrob Chemother; 2023 Jul; 78(7):1644-1648. PubMed ID: 37248664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of persisting SARS-CoV-2 infection in an immunocompromised patient with repeated nirmatrelvir/ritonavir courses: a case report.
    Lindahl AL; Ahava MJ; Haukipää M; Kreivi HR; Lipponen A; Kortela E
    Infect Dis (Lond); 2023 Aug; 55(8):585-589. PubMed ID: 37334428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of nirmatrelvir/ritonavir and remdesivir as treatment for SARS-CoV-2 infection in immunocompromised patients with hematologic malignancies. Series of four cases.
    Segura Fábrega A; Pérez Catalán I; Gómez Alfaro I; García Muñoz S; Roig Martí C; Rodríguez Lozano N; Folgado Escudero S; Varea Villanueva M; Gascón Buj A; Torres García M; Reig Valero R; Ferrando Piqueres R; Usó Blasco J
    Rev Esp Quimioter; 2023 Dec; 36(6):655-657. PubMed ID: 37786958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy.
    Ciccimarra F; Luxi N; Bellitto C; L' Abbate L; De Nardo P; Savoldi A; Yeomans A; Molokhia M; Tacconelli E; Trifirò G
    BioDrugs; 2023 Sep; 37(5):675-684. PubMed ID: 37148526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents.
    Mazzotta V; Cozzi Lepri A; Colavita F; Rosati S; Lalle E; Cimaglia C; Paulicelli J; Mastrorosa I; Vita S; Fabeni L; Vergori A; Maffongelli G; Carletti F; Lanini S; Caraffa E; Milozzi E; Libertone R; Piselli P; Girardi E; Garbuglia A; Vaia F; Maggi F; Nicastri E; Antinori A;
    J Med Virol; 2023 Jan; 95(1):e28186. PubMed ID: 36184918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
    Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
    Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature.
    Marangoni D; Antonello RM; Coppi M; Palazzo M; Nassi L; Streva N; Povolo L; Malentacchi F; Zammarchi L; Rossolini GM; Vannucchi AM; Bartoloni A; Spinicci M
    Int J Infect Dis; 2023 Aug; 133():53-56. PubMed ID: 37150351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19.
    Baldi F; Dentone C; Mikulska M; Fenoglio D; Mirabella M; Magnè F; Portunato F; Altosole T; Sepulcri C; Giacobbe DR; Uras C; Scavone G; Taramasso L; Orsi A; Cittadini G; Filaci G; Bassetti M
    Front Med (Lausanne); 2022; 9():1062450. PubMed ID: 36698815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection.
    Pasquini Z; Toschi A; Casadei B; Pellegrini C; D'Abramo A; Vita S; Beccacece A; Bussini L; Chionsini MC; Dentale N; Cantiani A; Lazzarotto T; Bartoletti M; Nicastri E; Zinzani P; Giannella M; Viale P
    Hematol Oncol; 2023 Dec; 41(5):904-911. PubMed ID: 37452579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral antivirals for COVID-19 among patients with cancer.
    Guermazi D; Arvanitis P; Vieira K; Warner JL; Farmakiotis D
    Support Care Cancer; 2024 Jul; 32(8):496. PubMed ID: 38980433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral combination regimens as rescue therapy in immunocompromised hosts with persistent COVID-19.
    Antonello RM; Marangoni D; Ducci F; Barbiero A; Manciulli T; Graziani L; Di Lauria N; Menicacci L; Paci L; Sordi B; Zammarchi L; Morettini A; Tomassetti S; Rossolini GM; Bartoloni A; Spinicci M
    J Chemother; 2024 Jun; ():1-5. PubMed ID: 38873733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England: a retrospective cohort study.
    Patel V; Yarwood MJ; Levick B; Gibbons DC; Drysdale M; Kerr W; Watkins JD; Young S; Pierce BF; Lloyd EJ; Birch HJ; Kamalati T; Brett SJ
    Curr Med Res Opin; 2024 Aug; 40(8):1323-1334. PubMed ID: 38975862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic Activity of Remdesivir-Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report.
    Gidari A; Sabbatini S; Schiaroli E; Bastianelli S; Pierucci S; Busti C; Saraca LM; Capogrossi L; Pasticci MB; Francisci D
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.